MAP2K7 and melanoma: To be specific, NRASQ61R-mutant melanoma receiving trametinib single-agent treatment obtained an ORR of 20% and a median PFS of 4 months in a phase II study.407 Forwardly, MEK inhibitor monotherapy has been approved in non-BRAF-mutation melanoma settings based on the results of phase III study, whereas the effect was not that satisfactory.